A cute kidney injury (AKI) is a devastating complication of cardiac surgery associated with prolonged hospitalization and short-and long-term mortality.
A threshold filter with α of 20 was applied to the highest and lowest 10% of measurements from the previous 10 seconds to exclude outliers resulting from mechanical interference by clinical personnel. The mean values of the remaining measurements, along with 6 previous 10-second mean values, are used to calculate the average urine flow rate. This value was divided by the patient's weight to report urine flow rates in milliliters per kilogram per minute or milliliters per kilogram per hour displayed graphically through ICM+ ( Figure 1B ).
In Vitro Validation
The gravimetric system was tested in a series of blinded experiments using 0.9% normal saline infused via standard intravenous tubing and an infusion pump (Alaris 8100 series; Becton-Dickinson, Franklin Lakes, NJ) connected to a urine drainage system (Foley Tray ADVANCE BARDEX; C.R. Bard, Murray Hill, NJ). The specific gravity of saline is 1.006; the specific gravity of urine is 1.005 to 1.035. 6 Computer-generated randomized flow rates were programmed to mimic clinical urine flow between 0 and 2.52 mL·kg −1 ·hour −1 for a hypothetical 70-kg patient. The latter urine flow rate was deemed to be a "high flow rate" in our previous study. 5 For the first simulation, 25 randomized flows equivalent to 0.72-2.52 mL·kg
for a 70-kg patient were evaluated over 75 minutes. The system outputs a value every 10 seconds, resulting in 451 measurements used to compare percent difference between infused and measured volumes. Subsequently, a period of 12 low flow rates was simulated utilizing rates from 0 to 1.3 mL·kg 
Pilot Clinical Use
The device complied with FDA 21 CFR 812.3 guidelines for a nonsignificant risk device and was approved by Johns Hopkins Medical Institution institutional review board (e-mail address: jhmeirb@jhmi.edu; phone: 410-955-3008). By using an Acute kidney injury after cardiac surgery is associated with increased morbidity and mortality. Methods for measuring urine output in real time may better ensure renal perfusion perioperatively in contrast to the current standard of care where urine output is visually estimated after empiric epochs of time. In this study, we describe an accurate method for monitoring urine output continuously during cardiopulmonary bypass. This may provide a means for setting patientspecific targets for blood pressure and cardiopulmonary bypass flow as a potential strategy to reduce the risk for acute kidney injury. Validation of a Real-Time Minute-to-Minute Urine Output Monitor and the Feasibility of Its Clinical Use for Patients Undergoing Cardiac Surgery institutional review board-approved protocol that required written informed consent, 30 patients were recruited as a substudy to a randomized trial of patients undergoing surgery using CPB (www.clinicaltrials.gov NCT00981474; Table) . The device was placed underneath the operating table. Urine outputs measured with the device during CPB were compared to visual measurements recorded in the medical record. Visual measurements were made by clinicians from the calibrated collection chamber of a urine drainage system using usual clinical care. Clinicians were blinded to urine output measured by the gravimetric device. They were aware, however, that their urine measurements would be compared with measurements from the device. The institutional review board waived the need for informed consent of clinicians for this comparison due to the routine clinical practice of these measurements.
Data Analysis
The in vitro testing was compared using percent difference and confidence interval (CI) analysis between the programmed infusion pump rate and the measured urine flow rate to verify device accuracy. The widths of the CIs were compared to the 95% CI of the infusion pump accuracy to verify adequate sample size. Percent difference was used to compare visual urine volume measurements during CPB with that measured with the gravimetric device. Results were analyzed using Microsoft Excel (Microsoft Corporation, Seattle, WA) and STATA (StataCorp LLC, College Station, TX).
RESULTS

In Vitro Results
Data for low and high urine flow rate simulations are shown in Figure 2 . The gravimetric system accurately tracked the manipulations to the infusion rate and volume. The median percent error across the high flow rate trial's 451 comparisons (−2.71% difference; 95% CI, −2.81% to −2.51% difference) and the low flow rate trial's 805 sample pairs (2.46% difference; 95% CI, 2.03%-2.88% difference) was within the infusion pump accuracy's 95% CI (±5% infusion error). This analysis demonstrates that the urine measurement system could accurately track flow in a dynamic simulation. 7 For reference, a previously marketed device (Urinfo 2000; Baxter, Inc, Deerfield, IL) showed a measurement error of 8% per hour. 8 
In Vivo Results
The urine measurement device was used successfully in all 30 patients. In 2 instances, urine output value was undecipherable from the handwritten perfusion record, underscoring the importance of automated, electronic record keeping. The median percent error in urine output measured between the device and 28 visual urine measurements was 19.3% (interquartile range, 7.2%-54.6%).
DISCUSSION
Based on in vitro testing, we found low measurement discrepancies between the volume of 0.9% saline infused into a urine drainage bag and that measured by the gravimetric device. Clinically, the device integrated into the operating room workflow. Given its height of 1.2 feet and footprint of <1 ft 2 , the device could be placed below the head of the operating table without interfering with its positioning and without being susceptible to inadvertent movement by the operating room team. There was a nearly 20% median difference (interquartile range, 7.2%-54.6%) between the clinically measured urine volume and that measured digitally with the gravimetric device similar to that previously reported. 8 In a previous study, we found that patients developing AKI after cardiac surgery had lower urine flow rates during CPB than those not developing AKI. 5 When urine flow was <1.5 mL·kg −1 ·hour −1 , every 0.5 mL·kg
increase in urine flow rate reduced the risk for AKI by 30%. We found that urine flow rate <0.5 mL·kg −1 ·hour −1 occurred in only 5.8% of the nearly 30% of patients with AKI, suggesting that oliguria-based definitions for AKI may be imprecise for the intraoperative setting. 5, 9 Other devices for measurement of urine output are available (Accuryn, Potrero Medical, San Francisco, CA; Criticore, Bard, Murray Hill, NJ; Renalguard, Renalguard Solutions Inc, Milford, MA; Output Medical, Chicago, IL). However, unlike our device, they do not integrate with 1-piece closed urinary catheter systems most commonly used in surgical patients. Given our observed error between clinical and digital urine volume measurements, the use of a more precise, real-time monitor of urine flow may provide clinicians with a more timely means to measure urine output more precisely.
Limitations to this study include the failure to consider the effect of varying specific gravity on urine volume inferred from a weight measurement. We are not aware of data on the rapidity of urine specific gravity changes during CPB or a means to measure it continuously. This likely would add minimal error to the volume and rate of urine during CPB over the range associated with AKI. 5 An approach to remedy this limitation would be scalar multiplication of urine weight by the preoperative urine specific gravity or by 1.02, which would assume a ±1.5% error given a urine specific gravity range of 1.005 to 1.035. 6 We observed negative percent error calculations during the low-flow in vitro experiments. This likely results from back pressure generated by the infusion pumps during changes in infusion rate that were detected by the high-precision scales.
7 Regardless, the device tested in this study was able to provide more granular and accurate real-time measurement of urine output than usual clinical measurements. Incorporation of these data into an electronic medical record may allow for more precision in patient management. E ·h −1 for a 70-kg patient). In the high rate trial (top), the total infused volume and respective rate was 143.2 mL (1.91 mL·h −1 ) and the measured amount was 138.6 mL (1.85 mL·h −1 ) for 3.21% difference in volume and 3.14% difference in overall rate. In the low rate trial (bottom), the total infused volume and respective rate was 95.7 mL (43.3 mL·h ) for 1.59% difference in volume and 2.5% difference in overall rate. The shaded area of the graph represents the ±5% error rate, which corresponds to the 95% confidence interval of the IV pump accuracy, and it can be seen that device tracks the infused data, and the measured amount is virtually always within the accuracy range.
